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OBJECTIVE — Slow nerve conduction velocity and reduction in response amplitude are
objective hallmarks of diabetic sensorimotor polyneuropathy. Because subjective or clinical
indicators of neuropathy do not always match well with the presence of abnormal nerve phys-
iology tests, we evaluated associations to nerve conduction in patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS — Nerve conduction studies were performed
inthedistalsuralandulnarsensorynervesandtheperonealmotornervein456individualswith
type 1 diabetes who participated in the follow-up visit of the EURODIAB Prospective Compli-
cations Study (EPCS). We used multivariate regression models to describe associations to de-
creased nerve conduction measures.
RESULTS — In addition to an effect of duration of diabetes and A1C, which were both
associated with low nerve conduction velocity and response amplitude, we found that the
presence of nephropathy, retinopathy, or a clinical diagnosis of neuropathy was associated with
low nerve conduction velocity and amplitude. In the case of nonproliferative retinopathy, the
odds ratio (OR) for being in lowest tertile was 2.30 (95% CI 1.13–4.67) for nerve conduction
velocity. A similar OR was found for each 2% difference in A1C (2.39 [1.68–3.41]).
CONCLUSIONS — We show that the presence of other microvascular diabetes complica-
tions, together with diabetes duration and A1C, are associated with low nerve conduction
velocityandamplituderesponseandthatcardiovasculardiseaseorriskfactorsdonotseemtobe
associated with these measures.
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D
iabeticneuropathiesarereportedto
affectupto66%ofindividualswith
type 1 diabetes, most frequently in
the form of polyneuropathy (54% of the
cohort), the remainder including focal,
visceralautonomic,andotheratypicalva-
rieties(1).However,prevalenceestimates
vary widely, most likely depending on
differences in patient selection, neuropa-
thydeﬁnition,andmethodsofassessment
(2) The underlying pathophysiology of
diabeticperipheralneuropathyisnotwell
understood beyond the marked impor-
tanceofchronichyperglycemiaasthekey
initiatorofneurovasculardamage(1,3,4).
Diabetic neuropathy is generally assessed
in clinical practice by a combination of
objectiveandsubjectivemeasures.Acon-
sensus report from the American Acad-
emy of Neurology concluded that a
combination of symptoms, signs, and
electrophysiological test results provides
the most accurate diagnosis of distal sym-
metric polyneuropathy (5). However, at
theonsetofneuropathy,clinicalmeasures
of dysfunction are often dissociated from
the presence of abnormalities on nerve
conduction studies (NCSs), which are
considered by many to be the gold stan-
dard for nerve damage and the most con-
sistent indicator of subclinical (largely
asymptomatic) neuropathy (6).
Previous studies generally showed
that age, male sex, height, diabetes dura-
tion, and glycemic control inﬂuence
nerve conduction (7,8). We have previ-
ously highlighted the importance of con-
ventional cardiovascular risk factors in
the etiology of clinical neuropathy in in-
dividuals with type 1 diabetes (9), but
their association to earlier abnormalities
in nerve conduction is less certain. Fur-
ther, the relation to the presence of other
complications, such as nephropathy and
retinopathy, remains unclear, largely
becausepreviousstudieswereunderpow-
ered and did not always have standard-
ized measures of both risk factors and
complications to enable simultaneous
assessment.
We therefore set out to study the
cross-sectional association among cardio-
vascular risk factors, anthropometric
measures, the presence of complications,
and ulnar, sural, and peroneal nerve con-
duction in individuals with type 1 diabe-
tes who participated in the EURODIAB
ProspectiveComplicationsStudy(EPCS).
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METHODS— The EURODIAB Study
recruited 3,250 patients with type 1 dia-
betes (1,668 men and 1,582 women;
mean  SD age 32.7  10.2 years and
duration of diabetes 14.7  9.3 years).
These participants were selected at ran-
dom from age, diabetes duration, and sex
strata from 31 diabetes clinics across Eu-
rope. Selection criteria and methods have
been described previously (10). Twenty-
seven centers participated in the follow
up of the EURODIAB cohort (the EURO-
DIAB Prospective Complications Study
[EURODIAB PCS]). We present data col-
lected in the 13 centers that participated
in the Nerve Conduction substudy, con-
ducted during the follow-up examina-
tions (1997–1999). Patients were
randomly selected by the EURODIAB
Data Coordinating Center, and a list of
selected patients was sent to the local
main investigator. Selected patients were
called for the nerve conduction study af-
ter they completed the main EURODIAB
PCS follow-up examination.
A total of 1,894 patients completed
the EURODIAB PCS follow-up examina-
tion. An NCS was performed in 634 pa-
tients. We excluded 44 patients because
of incomplete data on cardiovascular risk
factors; 130 patients were excluded be-
cause of incomplete nerve conduction
data, 91 of these were only missing data
from the sural nerve. Data from these 91
patients were initially included in analy-
ses of the peroneal and ulnar nerves, but
these results did not differ markedly from
a complete data analysis (data not
shown). Six patients were excluded be-
cause of extreme outlying values on nerve
conduction tests, yielding a set of 456 pa-
tients with complete data. It is likely that
some of these data were missing because
the true value of nerve conduction was
below the threshold of detection (i.e., the
true nerve conduction value is not zero/
missing, but rather too low to be mea-
sured); thus, we supplemented the
complete-case analyses, on which this ar-
ticle is based, with analyses using multi-
ple imputation techniques and single
imputation (using the ﬁrst percentile of
nerve conduction values as imputed
value) to explore the impact of missing
values on our results. We report primary
results based on complete-case analysis (456
patients)andprovideresultsfromthesupple-
mentary multiple and single imputation anal-
ysis for reference (supplementary methods,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc10-0456/DC1).
Measurements
Blood samples were obtained ideally after
an overnight fast. These were sent to a
central laboratory and analyzed for A1C,
total and HDL cholesterol, and triglycer-
ides(11).LDLcholesterolwascalculated.
To compare the results with those of the
DiabetesControlandComplicationsTrial
(DCCT), measured A1C values were con-
verted as reported previously (11) and
used in all subsequent analyses.
The urinary albumin excretion rate
was the average from two 24-h urine col-
lections.Aurinaryalbuminexcretionrate
of 20–200 g/min was deﬁned as mi-
croalbuminuria; a rate 200 g/min was
deﬁned as macroalbuminuria.
The presence and severity of diabetic
retinopathy were assessed from retinal
photographs(twoﬁeldspereye)obtained
withawide-anglecameraandscoredcen-
trally. Retinopathy for this analysis was
dichotomized as nonproliferative or
proliferative.
Cardiovascular disease (CVD) was
deﬁned as either a history of physician-
diagnosed CVD (e.g., previous myocar-
dial infarction, angina, coronary-artery
bypass grafting, or stroke) or ischemic
changes detected on a 12-lead electrocar-
diogram (classiﬁed by two observers ac-
cording to the Minnesota code).
Clinicalneuropathywasdiagnosedin
patientswithtwoormoreofthefollowing
four measures: the presence of one or
more symptoms, the absence of two or
more reﬂexes of the ankle or knee ten-
dons, a vibration perception threshold
that was abnormal for the patient’s age,
andabnormalautonomicfunction(lossof
heartratevariabilitywitharatioof1.04,
posturalhypotensionwithafallinsystolic
blood pressure of 20 mmHg, or both).
Descriptions of the speciﬁc tests have
been published previously (12). The
cutoff points and the deﬁnition of neu-
ropathy were established before any ex-
amination of the outcome data.
The NCSs were performed with stan-
dard electrophysiological and electro-
myographic equipment provided by
major manufacturers (e.g., Nicolet, Teca,
and Disa). Digital skin thermometers ac-
curate to 0.1°C and, when necessary, ap-
propriatewarmingmeasureswereusedto
ensure that skin temperatures were at
least32°C.Examinationswereperformed
by trained electrophysiologists with ex-
tensiveexperienceinrecordingandinter-
preting clinical data. Velocity was
determined for the distal sural and ulnar
sensorynervesandfortheperonealmotor
nerve (knee to ankle) unilaterally on the
nondominant side. Response amplitude
was measured overlying the dorsal sur-
face of the foot for the sural nerve, at the
ﬁfth ﬁnger for the ulnar nerve and over-
lying the extensor digitorum brevis mus-
cle for the peroneal nerve. All data were
collected using standard surface tech-
niques and speciﬁed anatomical land-
marks for both stimulation and recording
sites. Before testing of study participants,
all participating electrophysiologists at-
tended a standardization training meet-
ing, and all centers were certiﬁed by
submittingthreesatisfactorycompleteex-
aminations using speciﬁc study proce-
dures by the central reading site (J.C.A. at
the Albert Einstein College of Medicine,
New York, NY). Throughout the study, a
sample of approximately one-third of the
datafromeachcenterwasreviewedbythe
centralreadingsitetoensureoverallqual-
ity and continued adherence to study
procedures.
Statistical analysis
We present cross-sectional analyses from
the EPCS follow up visit. Statistical anal-
yses were performed with Stata software
(version 11; StataCorp, College Station,
TX). Characteristics of patients who did
and did not participate in the NCSs were
compared with the use of the Student t
test or Mann-Whitney U test where ap-
propriate. In the case of unequal vari-
ances, means were compared by
approximate inference based on the t
distribution.
Multivariate linear regression models
were used to describe the associations
among cardiovascular risk factors, anthro-
pometricmeasures,thepresence/severityof
complications, and ulnar, sural, and pero-
neal nerve conduction, which are reported
as unstandardized coefﬁcients. Data were
collected as crude data from each center;
therefore, models for nerve conduction
measureswereadjustedforage,sex,height,
diabetes duration, A1C, center, skin tem-
perature, and distance between electrodes
into the model. These covariates were pre-
speciﬁed as factors that may affect nerve
conduction based on previously published
evidence (13,14). Nerve conduction ve-
locity (NCV) and nerve conduction am-
plitude (NCA) for the three nerves were
standardized and summarized per indi-
vidual in a total z score, which was used
as an additional outcome in a separate
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conduction measure was deﬁned as be-
ing in the lowest tertile of ulnar, sural,
and peroneal NCV or NCA, and odds
ratios(ORs)forbeinginthisgroupwere
calculated using a multivariate logistic
regression model with adjustment for
the sample variables as mentioned
above.  coefﬁcients and ORs are given
with 95% CIs. Methods for the supple-
mentary multiple imputation analyses
are described in an online appendix.
RESULTS— Characteristics of the pa-
tients included in the current analyses
compared with those of all the EURO-
DIAB participants who completed the
EPCSfollow-upareshowninTable1.Pa-
tients in the NCS analysis set were
younger(36.8years),hadashorterdiabe-
tes duration (19.5 years), and had more
favorable levels of most cardiovascular
risks factors and a lower prevalence of
complications.Wecomparedthepatients
excluded from our NCSs because of miss-
ing values and found that they were older
(43.9years),hadlongerdiabetesduration
(25.2 years), and had higher levels of all
cardiovascular risk factors and complica-
tions. (The excluded patients had lower
average nerve conduction measures.) Un-
adjusted mean NCV and NCA values for
participants by complication status are
presented in Table 2. The associations
among cardiovascular risk factors, an-
thropometric measures, diabetes compli-
cations, and NCV/NCA are shown in
supplementary Tables 1A and 2A (avail-
able in an online appendix). Comparison
with results from the imputation analyses
of velocity/amplitude z scores are shown
in supplementary Tables 3A and 4A
(available in an online appendix).  coef-
ﬁcients denote the difference in NCV/
NCA per unit difference in each
determinant; e.g., for a 1-year increment
in age, ulnar NCV is 0.15 m/s lower.
We conﬁrm that duration of diabetes
and A1C were both negatively and statis-
tically signiﬁcantly associated with NCV
andNCAinallthreenerves.Wealsocon-
ﬁrm that the presence of nephropathy or
Table 1—Characteristics of all participants of the EURODIAB PCS and those who were
included in the Nerve Conduction substudy analysis
EURODIAB follow-up
Nerve conduction tests
(complete case)
n 1,886 456
Male sex (%) 52 50
Caucasian (%) 92 99
Age (years) 38.6 (26.2; 58.3) 36.8 (26.5; 55.3)
Duration of diabetes (years) 20.5 (9.7; 39.1) 19.5 (9.4; 33.7)
A1C (% of hemoglobin) 8.34 (6.4; 11.3) 8.2 (6.4; 10.9)
Systolic blood pressure (mmHg) 121.1  18.6 117  16.4
Diastolic blood pressure (mmHg) 74  11.9 74  10.7
Weight (kg)
Men 75.9  10.7 74.5  8.9
Women 64.7  10.8 63.2  10.3
Height (cm)
Men 174.8  7.5 174  7.4
Women 162.6  7.1 162.8  7.0
Total cholesterol (mmol/l) 5.33  1.19 5.24  1.1
Triglycerides (mmol/l) 0.99 (0.52; 2.66) 0.915 (0.47; 2.21)
Smoking (ever/current) 707 (38) 145 (31)
Alcohol (10 units/week) 471 (28) 99 (25)
CVD 211 (11) 35 (8)
Microalbuminuria (20–200 g/min) 306 (18) 62 (15)
Macroalbuminuria ( 200 g/min) 216 (9) 11 (3)
Nonproliferative retinopathy 817 (53) 205 (52)
Proliferative retinopathy 305 (20) 47 (12)
Neuropathy 667 (35) 107 (23)
Data are means  SD, skewed distribution: median (5th; 95th percentile), or n (%) unless otherwise
indicated.
Table 2—NCSs of ulnar and distal sural sensory nerves and the peroneal motor nerve (knee to ankle) unilaterally on the nondominant side in
the EURODIAB PCS at follow-up
Ulnar Sural Peroneal
Velocity (m/s) Amplitude (mV) Velocity (m/s) Amplitude (mV) Velocity (m/s) Amplitude (mV)
CVD
None 51.2  6.3 18.6  12.3 45.1  7.0 10.3  7.4 43.9  4.5 5.4  3.2
Present 48.3  6.7 16.8  10.9 44.7  6.8 8.4  6.7 43.0  4.0 5.7  4.5
Neuropathy
None 51.6  5.7 19.7  12.5 45.4  7.2 11.0  7.7 44.3  4.5 5.7  3.3
Present 48.7  7.8 14.8  10.3 44.1  6.3 7.4  5.5 42.6  4.4 4.3  3.1
Albumin excretion
Normal 51.3  6.1 18.9  12.2 45.8  7.0 10.8  7.8 44.3  4.4 5.5  3.1
Microalbuminuria 49.0  7.0 15.6  10.7 42.1  7.0 7.7  5.4 41.4  4.6 4.1  2.3
Macroalbuminuria 48.0  8.7 11.5  11.1 40.3  4.6 5.1  4.0 41.4  3.6 4.0  3.1
Retinopathy
None 52.1  5.9 20.9  13.2 47.6  7.7 12.4  9.1 46.0  3.9 5.9  4.0
Nonproliferative 51.4  6.8 18.6  11.8 45.0  6.8 9.8  6.2 43.6  4.6 5.1  2.8
Proliferative 47.5  5.9 11.7  8.6 41.2  5.3 6.5  4.7 40.9  4.1 3.8  2.7
Data are means  SD and are unadjusted from the complete-case analysis.
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ropathywasassociatedwithlowNCVand
NCA z scores. Age, sex, and height have
major effects on nerve conduction in
health. These effects were also seen in our
population. Sex was not consistently sig-
niﬁcantly associated with the NCV and
NCAofindividualnerves.Weightwasas-
sociated with a higher NCV z score, but
this effect was not observed for NCA. The
association between height and lower
NCV or NCA was only present in the
nerves of the lower extremity. ORs for
having a z score in the lowest tertile of
NCV/NCA by diabetes complication sta-
tus are shown in Fig. 1. All diabetic mi-
crovascular complications were
associated with lower nerve conduction
measures. Microalbuminuria was associ-
ated with increased odds of low NCV or
NCA (OR 2.25 [95% CI 1.15–4.40] and
2.29 [1.12–4.66], respectively). In the
case of nonproliferative retinopathy, val-
ues were 2.30 [1.13–4.67] and 2.29
[1.15–4.58] for NCV and NCA, respec-
tively. A similar increase in the odds of
low NCV or NCA was found for each 2%
difference in A1C (2.39 [1.68–3.41] and
2.47 [1.72–3.54], respectively) or a dif-
ference of 10 years of duration of diabetes
(3.09[2.09–4.57]and3.01[2.03–4.47],
respectively). We repeated our analyses
onasubsetofthepatientswithoutclinical
signs of neuropathy. This restriction did
notmateriallyaffectourﬁndings(datanot
shown).
Results from the subsidiary analyses
using imputed datasets yielded results
that were broadly similar to those for the
complete-case analysis (supplementary
Tables 1A and 2A).
CONCLUSIONS— We showed in
oneofthelargestsetsofpatientswithtype
1 diabetes to date that, in addition to du-
ration of diabetes and level of A1C, the
presence of other microvascular diabetes
complicationsisassociatedwithlowNCV
and NCA. We did not ﬁnd associations
with blood pressure, lipid levels, BMI,
waist-to-hip ratio, smoking, or alcohol
consumption.
The EURODIAB PCS offers the possi-
bility to study complications of type 1 di-
abetes, because it provides a large,
multicenter, European cohort of patients
attending a clinic at least once a year. In
addition, all participating centers used
similarstandardizedmethodstoobtainall
measures. Therefore, compared with
otherstudies,ourstudyonnerveconduc-
tion has the strength of containing exten-
sive information on these measures for
634 patients with type 1 diabetes, and we
have the ability to take this information
into account in our analyses.
Unfortunately, many patients had
missing values on nerve conduction.
Complete-case analysis could therefore
be subject to a degree of selection bias
because the term “missing” could reason-
ably be applied to one of three circum-
stances: 1) the speciﬁc nerve was never
tested (e.g., the patient did not permit
testing of the ulnar nerve due to pain); 2)
data were collected, but judged to be
technically unacceptable (e.g., the sen-
sory response was distorted by a pro-
longed stimulus artifact); or 3) correct
procedures were followed, but the nerve
response was below the detection thresh-
olds using the applied surface recording
procedures (i.e., patients with advanced
neuropathy have an increased risk of ob-
taining a missing value). To explore the
effect of missing values, we performed
subsidiary analyses using single or multi-
ple imputation methods. Multiple impu-
tation is best applied when data are
missing at random, a condition that is de-
monstrably not met in our data. Single
imputation analysis, which assigns the
lowest observed NCS values to those with
a missing value, does not deal with the
variance structure of the imputed values
and may therefore lead to incorrectly nar-
row CIs. Because neither imputation
method is satisfactory in our dataset, we
focused on the complete-case analysis
and provide the results of the subsidiary
imputation analyses as reference. It is im-
portant to note that our main results and
conclusions were not dependent on the
chosen statistical method, indicating that
the observed associations are unlikely to
have been introduced by participant se-
lection. It is known that age, sex, and
height have major effects on nerve con-
Figure 1—OR of the lowest tertile of the velocity (left) and amplitude z score (right), adjusted for age, sex, height, center, diabetes duration, A1C,
and determinants of nerve conduction measures (skin temperature and distance between electrodes). z scores are calculated from a summed score of
standardized NCV/NCA from ulnar and distal sural sensory nerves and the peroneal motor nerve (knee to ankle) unilaterally on the nondominant
side. *Microalbuminuria (microalb): 20–200 g/min; macroalbuminuria (macroalb) 200 g/min. **Prevalence of CVD. Composite score of
symptoms, absent reﬂexes, abnormal vibration perception threshold, or autonomic dysfunction. non-prolifera, nonproliferative.
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These associations also exist in our popu-
lation of type 1 diabetic patients, but we
cannot investigate from our data whether
the association goes beyond the effects in
health.
Our study is based on a population of
European Caucasian patients with type 1
diabetes, and one cannot readily general-
ize these ﬁndings to a broader diabetes
population. It is possible that different as-
sociations or effect magnitudes are appli-
cable among individuals with type 2
diabetes or in other populations. The pa-
tients included in our analysis were
younger and had fewer potential risk fac-
tors than the rest of the EURODIAB pop-
ulation, but because the ﬁndings of
imputation analysis conﬁrm the ﬁndings
from the complete-case analysis, we are
conﬁdent that our conclusions are repre-
sentative of the EURODIAB population
and that the mechanisms of neuropathy
development are likely to be similar for a
majority of patients.
A direct comparison of different co-
variatesonnerveconductionwillincrease
the clinician’s ability to identify those pa-
tients most likely to have neuropathic
damage. Other studies have previously
shown that duration of diabetes and gly-
cemiccontrolarerelatedtonerveconduc-
tion measures. The DCCT showed the
importance of glycemic control in the de-
velopment of neuropathy and also
showed that even in patients without di-
agnosableneuropathytherewasarelation
between glycemic control and nerve con-
duction (15). A cross-sectional analysis of
162patientswithtype1diabetesand267
patients with type 2 diabetes in the Early
Diabetes Intervention Trial found that
age,sex,andanthropometricfactorswere
related to nerve conduction measures,
with no difference by diabetes type (16).
A smaller study of 25 patients with type 1
diabetes and 72 with type 2 diabetes
found an association among glycemic
control, male sex, diabetes duration, and
height and lower NCV or NCA, but no
impact of weight, systolic and diastolic
blood pressure, neuropathy duration,
andplasmacholesterolortriglyceridelev-
els (17). Our study conﬁrms the associa-
tion with male sex, glycemic control, and
diabetes duration on objective measures
of nerve conduction.
Several of the smaller studies per-
formed to date have examined the effect
of cardiovascular risk factors on nerve
conduction. Some found no impact of
weight, systolic and diastolic blood pres-
sure, neuropathy duration, and plasma
cholesterol or triglyceride levels (17) but
alsosuggestedthatvascularfactorspartic-
ipate in the development of neuropathy
(18), whereas others reported an inde-
pendent association between pulse pres-
sure and hypertension and diabetic
peripheral neuropathy in patients with
type 2 diabetes (19). A prospective study
of57patientswithtype2diabetesdidnot
conﬁrm these ﬁndings (20). An associa-
tion between elevated triglycerides and
sural nerve myelinated ﬁber density has
been reported (21). Because of their small
size, these studies had a limited ability to
adjust for potential confounding. Based
onourﬁndings,theredoesnotseemtobe
a clear association of NCSs with cardio-
vascularriskfactors,takingimportantco-
variates into account, and therefore the
level of cardiovascular risk factors cannot
help a clinician in selecting patients with
neuropathic damages.
The strong association among reti-
nopathy, nephropathy, and neuropathy
has been noted by many others (1, 4, 9,
22, 23). A substudy from the Rochester
Diabetic Neuropathy Study (RDNS) co-
hort,involving238patientswithdiabetes
(80% type 2 diabetes), found that sub-
clinical nerve dysfunction precedes the
diagnosis of polyneuropathy and showed
that a composite score of nerve conduc-
tionabnormalitywasunequivocallysupe-
rior to clinical impairment, symptoms, or
quantitative sensation testing in identify-
ing patients with monotone worsening
(6). The RDNS further showed that 24-h
microalbuminuria was a signiﬁcant risk
factor for worsening of nerve conduction
among patients with diabetes (6) and that
microvessel disease, chronic hyperglyce-
mic exposure, and type of diabetes were
associated with the severity of diabetic
polyneuropathy (24). Our ﬁndings con-
ﬁrm that there is a close relation between
the presence of microvascular complica-
tions and reduced NCV/NCA, indicating
that the deleterious microvascular effects
of long-term exposure to hyperglycemia
develop in parallel, even if the clinical
presentation of symptoms may suggest a
sequence.
In the EURODIAB population a
strong association between neuropathy
and a history of CVD has been reported
previously. However, there was only a
weaker association between the develop-
ment of neuropathy and other markers of
microvessel disease (9).
We considered several potential ex-
planations for our ﬁnding of no associa-
tion between cardiovascular disease and
NCS results. Although the patients in our
analysismaynotbefullyrepresentativeof
thecompleteEURODIABpopulation,this
selection is unlikely to affect the direction
and magnitude of risk factor associations
within the substudy. We performed a
subanalysis excluding those with a posi-
tive neuropathy score at baseline and still
found no association with CVD. It is con-
ceivable that our assessment of CVD,
which is based on physician-diagnosed
CVDandveriﬁedischemicchangesonthe
electrocardiogram, lacks the precision
needed to detect subtle associations with
NCSs. However, we believe that our
methodmayhavealowspeciﬁcitybuthas
a good sensitivity to detect CVD. We
found that 35 of 456 patients had CVD
according to our deﬁnition, whereas 11
hadmacroalbuminuriaand47hadprolif-
erative retinopathy. Any true association
that we may have missed is therefore
likely to be of small magnitude compared
with those seen with the microvascular
complications. Likewise, the results did
not differ in the imputed datasets.
This ﬁnding supports the theory that
there is a common pathophysiological
pathway of microvessel disease, which
has no direct relation to macrovascular
disease. Because we did not ﬁnd clear as-
sociations with other cardiovascular risk
factors, the pathogenic effects of hyper-
glycemiaappeartobethemainetiological
factor. However, this is a cross-sectional
study, and thus we cannot infer any
causal connection to risk factors. A pro-
spectivestudywithdetailedassessmentof
microvascular pathophysiology and NCS
progression from baseline would be nec-
essary to answer this question.
It has been documented that neurop-
athyoftenissubclinical(15,25).Basedon
our ﬁnding of close associations among
markers of microvessel disease, the ﬁnd-
ing of any indication of incipient mi-
crovessel disease should therefore alert
the clinician toward thinking that the pa-
tient has an increased risk of having neu-
ropathy. Therefore, if such a patient does
not show signs of neuropathy on the clin-
ical neurological assessment, referral for a
NCS may be worth considering.
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